Exhibit 99.2
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
On May 3, 2021, Trinseo S.A., (together with its subsidiaries, the “Company” or “Trinseo”), completed its previously-announced acquisition of the polymethyl methacrylates (“PMMA”) and activated methyl methacrylates (“MMA”) business (together, the “PMMA business”) of Arkema S.A., (“Arkema” or the “Seller”) through the purchase of shares of certain subsidiaries of Arkema (the “Acquisition”), for a purchase price of €1.12 billion (approximately $1.36 billion), subject to customary working capital and other post-closing adjustments. The Acquisition was completed pursuant to the Share Purchase Agreement, dated March 19, 2021 (the “SPA”), by and between the Company and Arkema.
The Acquisition was funded using the net proceeds from the Company’s new financing arrangements, including $450.0 million from its 2029 Senior Notes issued on March 24, 2021 and $750.0 million of incremental term loan borrowings under the 2028 Term Loan B entered into in conjunction with closing of the transaction (together, the “Financing”), as well as available cash.
The unaudited pro forma combined statement of operations for the year ended December 31, 2020, gives effect to the Acquisition and Financing (together, the “Transactions”) as if they had been consummated on January 1, 2020. The unaudited pro forma combined balance sheet as of December 31, 2020 gives effect to the Transactions as if they had been consummated on December 31, 2020.
The following unaudited pro forma combined financial information and related notes were derived from (i) the audited consolidated financial statements of Trinseo for the year ended December 31, 2020, and (ii) the audited combined carve-out financial statements of the Arkema business for the year ended December 31, 2020. The historical PMMA business (also referred to as the “Arkema business,” the “Mallarmé business,” or the “Mallarmé combined group”) and the audited combined carve-out financial statements and related notes thereto also included the operations of a manufacturing site in South Korea. However, this site is not within the scope of the Acquisition. As such, within this document, we distinguish between the historical operations of the acquired business, inclusive of South Korea operations, as the “Arkema business” and the results of the acquired business, excluding the South Korea operations, as the “PMMA business.”
The pro forma adjustments consist of transaction accounting adjustments reflecting (i) the exclusion of the South Korea site and related operations, which are included in the historical results of the Arkema business but are not included in the scope of the Acquisition (“Excluded South Korea Business”) (ii) the impact of the PMMA Acquisition (“Acquisition Pro Forma Adjustments”), and (iii) other transaction accounting adjustments related to Financing (“Financing Pro Forma Adjustments”).
The accompanying unaudited pro forma financial information was prepared in accordance with Article 11 of the U.S. Securities and Exchange Commission’s Regulation S-X.
Assumptions underlying the pro forma adjustments are described in the accompanying notes, which should be read in conjunction with the unaudited pro forma combined financial information. Management believes that these assumptions and adjustments are reasonable and appropriate under the circumstances and are factually supported based on information currently available.
The preliminary purchase price allocation was made using the best estimates of fair value, which are dependent upon certain valuations that are not yet final. As a result, the unaudited pro forma purchase price adjustments related to the acquisition are preliminary and subject to further adjustments as additional information becomes available and as additional analyses are performed.